German health reform hits Beiersdorf's sales:
This article was originally published in Clinica
Executive Summary
Beiersdorf's domestic medical sales continue to be hit by the effects of German health reform and subsequent uncertainty following "complicated" regulatory change. Total sales in this division fell 1.6% to DM756 million ($427 million) in the first half of 1998, as a result of reduced sales in Germany. The Hamburg-based company's group sales were DM3,420 million, up 6%, with net income of DM159 million, compared with DM146 million - excluding restructuring costs - in the previous first half.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.